Tirzepatide and Semaglutide are the most popular weight-loss drugs on the market. Both drugs have proven to be safe and highly effective in weight control trials, and they have a variety of benefits for those who want to lose weight.
Tirzepatide is a once-weekly injection that has been proven to help people lose up to 22% of their body weight in 28 weeks. Semaglutide has been shown to help people lose up to 15.0% of their body weight in the same time frame. Semaglutide and Tirzepatide are both FDA-approved and have years of research behind them.
In addition, Semaglutide and Tirzepatide are drugs that show the potential to improve metabolic health and reduce A1C hemoglobin. Scientific data shows that they may also reduce the likelihood of cardiovascular events of stroke and improve
Both medications are used to help people with diabetes control their sugars.
The FDA approved semaglutide for weight management in 2014. Semaglutide is a glucagon-like peptide-1 receptor or GLP -1 drug under Ozempic, Wegovy, and Rybelsus. Two of the three products, Ozempic and Rybelsus, are designed for type 2 diabetics, and Wegovy is specifically indicated for treating obesity.
Semaglutide is a once-weekly medication in the GLP-1 receptor agonist class of drugs. It was originally for adults with type 2 diabetes, in addition to diet and exercise, to improve glucose. Semaglutide is also used to reduce the risk of major cardiovascular events like heart attacks, strokes, or death in those with type 2 diabetes and heart disease. It helps release insulin and lowers the amount of glucose triggered by the liver when glucose rises at mealtimes. It also slows the absorption of glucose.
Semaglutide suppresses appetite. It increases the production of insulin, a hormone created in the pancreas that regulates blood sugar. It balances out insulin and curbs appetite, which allows you to shed pounds by eating less.
Tirzepatide is a once-a-week injection, and when used in addition to diet and exercise, it improves blood sugar in adults with type 2 diabetes. The FDA approved Tirzepatide in May 2022 for type 2 diabetics.
Tirzepatide is formally a dual glucose-dependent on insulinotropic polypeptide (GIP) and glucagon-like peptide -1 (GLP-1) receptor agonist. It works by acting like GLP-1 and GIP, two hormones released by your digestive system after you eat to help you control your blood sugar.
These hormones tell your body to release more insulin, less sugar, and slow digestion.
What is most important about Tirzepatide is it is being used as a weight control medication. When used in addition to diet and exercise, it improves blood sugar in adults with type 2 diabetes. Users have been shown to lose up to 22% more weight on Tirzepatide than any other weight loss medication.
Semaglutide vs Tirzepatide
Tirzepatide and semaglutide have proven to be highly effective in helping patients lose weight relatively quickly. Both are glucagon-like peptides (GLP-1) receptor agonists, but Tirzepatide is also a glucose-dependent insulinotropic polypeptide (GIP). Both drugs increase insulin sensitivity, triglyceride clearance, lipolysis (fat utilization for fuel) metabolic rate, and decrease appetites, fat storage, and digestion.
Tirzepatide is a more effective weight loss supplement than semaglutide, but both medications significantly reduce body weight. In addition, Tirzepatide and semaglutide are associated with equal value in lowering blood sugar levels.
If you are considering weight loss and are considering Semaglutide or Tirzepatide and would like to find out more about these weight loss medications, contact Aging Young Aesthetics or fill out the request form at https://agingyoungaesthetics.com You can also call us to book a consultation at 218-481-1800.
All weight loss appointments are made through Telehealth using a HIPAA-compliant portal. Consults are free of charge. We offer services in multiple states and have providers to refer you to if needed. Medications are shipped directly to you from the compounding pharmacy. We do accept HSA and FSA.